Testing galcanezumab for Alzheimer's disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests whether galcanezumab, an antibody injection, can help people with mild-to-moderate Alzheimer's disease. It is for patients who have a confirmed Alzheimer's diagnosis and a caregiver who can support them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 50 and 90 years old
- Diagnosed with probable Alzheimer's disease by standard criteria
- Mild to moderate dementia (specific memory and thinking test scores)
- Evidence of Alzheimer's brain changes (from PET scan or spinal fluid test)
- Have a reliable caregiver who spends at least 8 hours per week with you
- If taking memory or psychiatric medications, dose must be stable for the past 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special near-infrared light device, combined with the medication lecanemab, can help people with mild Alzheimer's disease. It aims to see if the light therapy can slow down memory loss and improve daily function.
This trial tests a drug called donanemab in people who have early signs of Alzheimer's disease (amyloid buildup in the brain) but are still thinking clearly. The goal is to see if the drug can slow or prevent cognitive decline before memory problems start.
This trial tests a medication called lecanemab for people with early onset familial Alzheimer's disease. It aims to see if the drug can help slow cognitive decline in those with confirmed signs of Alzheimer's in their brain.
This Phase 2 study tests whether sargramostim (a GM-CSF related medicine) is safe and can slow or improve Alzheimer’s symptoms. You might be a good fit if you have mild or moderate Alzheimer’s, positive amyloid testing, and can complete frequent visits with a close caregiver who knows you well.
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
This study tests a drug called Lecanemab in people with early Alzheimer's. It uses a blood test to see how well the drug works. You may qualify if you have mild Alzheimer's or mild cognitive impairment due to Alzheimer's and have a positive amyloid test.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.